Category

Research

Osimertinib promising for EGFR-mutant NSCLC with leptomeningeal metastases ResearchTreatments

Osimertinib promising for EGFR-mutant NSCLC with leptomeningeal metastases

*December 2019* Patients with EGFR-mutant (m) non-small-cell lung cancer (NSCLC) and leptomeningeal metastases (LM) respond favorably to high daily doses of osimertinib, phase 1 BLOOM study data suggest. Myung-Ju Ahn (Sungkyunkwan University School of Medicine, Seoul, Republic of Korea) and study co-authors say that “osimertinib has the potential to become a…
laurabbook@gmail.com
January 18, 2020
dana farber logo
Dana-Farber Cancer Institute to Establish Chen-Huang Center for EGFR Mutant Lung Cancers FundingResearch

Dana-Farber Cancer Institute to Establish Chen-Huang Center for EGFR Mutant Lung Cancers

*January 2020* Dana-Farber Cancer Institute will create the Chen-Huang Center for EGFR (epidermal growth factor receptor) Mutant Lung Cancers to stimulate research, promote clinical trials, and strengthen the Institute’s capabilities for studying and treating lung cancer. The Chen-Huang Center is being established with a $5 million gift from Winston Chen,…
laurabbook@gmail.com
January 18, 2020
EGFR Resisters logo
Project PRIORITY: Why it matters to the EGFR-positive lung cancer community AdvocacyCoping With CancerResearch

Project PRIORITY: Why it matters to the EGFR-positive lung cancer community

*December 2019* Project PRIORITY (Patient Reported Initiative On Resistance, Incidence, Treatment studY), is a collaboration between LUNGevity Foundation and the EGFR Resisters—a grassroots, patient-driven community dedicated exclusively to changing EGFR-positive lung cancer into a manageable chronic disease. Goal of Project PRIORITY To understand unmet needs of the EGFR-positive lung cancer…
laurabbook@gmail.com
December 20, 2019
EGFR Resisters logo
New Clinical Trials ResearchTreatments

New Clinical Trials

*November 2019* Phase II progression on any TKI with a new 3rd generation TKI, lazertinib. Location: Montefiore/Einstein in NYC. More information. The JNJ-372 (or JJNJ-61186372) was recently updated with the addition of Lazertinib as one of its arms to be given in combo with JNJ-372 drug or separately and is/or…
laurabbook@gmail.com
November 8, 2019
New Data Challenge Current Standard in Treating EGFR+ Lung Cancer ResearchTreatments

New Data Challenge Current Standard in Treating EGFR+ Lung Cancer

*September 2019*  by Dr. Mark Kris for Medscape This is Mark Kris from Memorial Sloan Kettering. Just when we thought we were all set with EGFR, suddenly we have some disruptive information that challenges how we're going to treat patients with EGFR-mutated cancers. At the American Society of Clinical Oncology…
laurabbook@gmail.com
November 8, 2019
targeted oncology
Analyzing Best Practices for Targeting EGFR Resistance Mutations in EGFR+ NSCLC ResearchTreatments

Analyzing Best Practices for Targeting EGFR Resistance Mutations in EGFR+ NSCLC

*June 2019*  by Nichole Tucker for Targeted Oncology Tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor receptor (EGFR) have made a well-documented impact on outcomes for patients with non–small cell lung cancer (NSCLC) who harbor EGFR mutations; the challenge is once a patient develops resistance to an EGFR TKI. Two abstracts…
laurabbook@gmail.com
November 8, 2019
Hypofractionated EGFR tyrosine kinase inhibitor limits tumor relapse through triggering innate and adaptive immunity ResearchTreatments

Hypofractionated EGFR tyrosine kinase inhibitor limits tumor relapse through triggering innate and adaptive immunity

*August 2019*  Science Immunology Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are a first-line therapy for rapidly killing tumors such as those associated with non–small cell lung cancer by blocking oncogenic receptor signaling, but tumor relapse often occurs. Here, we have observed that hypofractionated EGFR TKI treatment (HypoTKI)…
laurabbook@gmail.com
September 25, 2019